You are here

  • Home
  • Archive
  • Volume 89, Issue 10
  • [18F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia

Article Text

Article menu

Download PDFPDF

Neurodegeneration
Research paper
[18F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia
  1. W R Bevan-Jones1,
  2. Thomas E Cope2,
  3. P Simon Jones2,
  4. Luca Passamonti2,
  5. Young T Hong3,
  6. Tim D Fryer3,
  7. Robert Arnold1,
  8. Kieren S J Allinson4,
  9. Jonathan P Coles5,
  10. Franklin I Aigbirhio3,
  11. Karalyn Patterson2,6,
  12. John T O’Brien1,
  13. James B Rowe2,6
  1. 1 Department of Psychiatry, University of Cambridge, Cambridge, UK
  2. 2 Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
  3. 3 Wolfson Brain Imaging Centre, University of Cambridge, Cambridge, UK
  4. 4 Department of Pathology, Addenbrooke’s Hospital, Cambridge, UK
  5. 5 Division of Anaesthesia, University of Cambridge, Cambridge, UK
  6. 6 Cognition and Brain Sciences Unit, Medical Research Council Cognition and Brain Sciences Unit, Cambridge, UK
  1. Correspondence to Dr W R Bevan-Jones, Department of Psychiatry, University of Cambridge, HerchelSmith Building, Cambridge Biomedical Campus, Hills Road, Cambridge CB20SZ, UK; wrb22{at}medschl.cam.ac.uk

Abstract

Introduction Semantic dementia, including the semantic variant of primary progressive aphasia (svPPA), is strongly associated with TAR-DNA binding protein 43 (TDP-43) type C pathology. It provides a useful model in which to test the specificity of in vivo binding of the putative tau ligand [18F]AV-1451, which is elevated in frontotemporal lobar degeneration tauopathies.

Methods and results Seven patients (five with svPPA and two with ‘right’ semantic dementia) and 12 healthy controls underwent positron emission tomography brain imaging with [18F]AV-1451. Two independent preprocessing methods were used. For both methods, all patients had clearly elevated binding potential (BPND (non-displaceable binding potential)) in temporal lobes, lateralising according to their clinical syndrome and evident in raw images. Region of interest analyses confirmed that BPND was significantly increased in temporal regions, insula and fusiform gyrus, consistent with those areas known to be most affected in semantic dementia. Hierarchical cluster analysis, based on the distribution of [18F]AV-1451 binding potential, separated semantic dementia from controls with 86% sensitivity and 100% specificity.

Conclusions [18F]AV-1451 binds in vivo regions that are likely to contain TDP-43 and not significant tau pathology. While this suggests a non-tau target for [18F]AV-1451, the pathological regions in semantic dementia do not normally contain significant levels of recently proposed ‘off target’ binding sites for [18F]AV-1451, such as neuronal monoamine oxidase or neuromelanin. Postmortem and longitudinal data will be useful to assess the utility of [18F]AV-1451 to differentiate and track different types of frontotemporal lobar degeneration.

This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/

https://doi.org/10.1136/jnnp-2017-316402

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Introduction

    The importance of biomarkers in neurodegenerative disorders is well established. Positron emission tomography (PET) has played an important role in biomarker development, illustrated by the impact of the Pittsburgh compound B on both research and clinical practice in Alzheimer’s disease.1 While beta-amyloid is central to the neuropathology of Alzheimer’s disease, in the vast majority of cases of frontotemporal lobar degeneration, the pathology is characterised by misfolding and aggregation of either tau (~40%) or TDP-43 (~50%), with fewer cases of fused in sarcoma pathology (<10%).2–4 A major aim for clinical research and drug development has been the development of biomarkers that enable pathological classification and longitudinal assessment in vivo, with quantitative and qualitative differentiation of neurodegenerative syndromes based on their underlying proteinopathy: tau versus TDP-43 versus beta-amyloid.

    The radioligand [18F]AV-1451 was developed from compound screening in Alzheimer’s brains and is selective for tau versus beta-amyloid and versus alpha-synuclein.5 In vitro and in vivo studies have confirmed that [18F]AV-1451 binding in Alzheimer’s disease correlates strongly with phenotypical variation,6 clinical severity and Braak stage.7–9 There are fewer studies in frontotemporal lobar degeneration, but [18F]AV-1451 has also been shown to be sensitive in vivo to frontotemporal dementia associated with mutation of the microtubule-associated protein tau (MAPT) gene10–12 and in progressive supranuclear palsy.13 There is also evidence of modest binding to primary tauopathies in postmortem studies.14 However, the specificity of [18F]AV-1451 for tau pathology remains controversial.

    Here, we test the properties of [18F]AV-1451 in semantic dementia, including the semantic variant of primary progressive aphasia (svPPA) and its non-dominant homologue, right semantic dementia (R-SD). Both syndromes display TDP-43 pathology in 75%–90% of cases,15 16 with tau pathology rarely present at postmortem. We test two complementary hypotheses:

    1. In clinically diagnosed semantic dementia (likely TDP-43 pathology), the non-displaceable binding potential (BPND) of [18F]AV-1451 is not increased compared with healthy older adults.

    2. Independent of absolute levels of [18F]AV-1451 BPND, the distribution of binding across brain regions is similar in patients and healthy controls.

    Methods

    This study formed part of the Neuroimaging of Inflammation in Memory and Related Other Disorders study.17 The study protocol was approved by the UK National Research Ethics Service, East of England, Cambridge Central Research Ethics Committee (reference: 13/EE/0104) and the Administration of Radioactive Substances Advisory Committee. Five participants with svPPA and two with R-SD were recruited from the specialist clinic for frontotemporal dementia at the Cambridge University Hospitals National Health Service Foundation Trust. Participants were diagnosed according to published consensus criteria.18 Four of the seven participants had available biomarkers for Alzheimer’s pathology. Case L5 had a negative Pittsburgh compound B PET, whereas cases R3, L6 and L7 had cerebrospinal fluid beta-amyloid, total tau and ratio levels not supportive of Alzheimer’s disease. Clinical vignettes and neuropsychological test scores are summarised in table 1. Twelve similarly aged healthy participants acted as controls.

    View this table:
    Table 1

    Demographic, clinical, neuropsychological (ACE-R, FAB and PPT) and diagnosis for each participant with semantic dementia and for the group of 12 controls

    MRI and PET imaging

    Each participant underwent T1-weighted MRI (3T Siemens Trio or 3T Siemens Prisma, MPRAGE sequence, 1 mm isotropic voxels) before PET. Manufacture of [18F]AV-1451 used synthetic methods developed by Avid Radiopharmaceuticals, modified for GE TracerLab FX-FN synthesizer at the Wolfson Brain Imaging Centre, Cambridge. A GE Discovery 690 PET/CT scanner was used. A total of 370 MBq of [18F]AV-1451 was injected over 30 s at the onset of a 90 min scan. Emission data were reconstructed in 58 contiguous time frame images. Each emission frame was reconstructed using the PROMIS 3D filtered back projection algorithm into a 128×128 matrix 30 cm transaxial field of view, with a transaxial Hann filter cut-off at the Nyquist frequency.19 Corrections were applied for randoms, dead time, normalisation, scatter, attenuation and sensitivity. Each emission image series was aligned to correct for patient motion during data acquisition (www.fil.ion.ucl.ac.uk/spm/software/spm8). The BPND was determined by kinetic modelling with a simplified reference tissue model. The reference tissue was defined in the superior grey matter of the cerebellum, using a 90% grey matter threshold on the grey matter probability map produced by SPM8, smoothed to the PET resolution. The superior cerebellum was chosen as a reference region as it is unlikely to contain substantial pathology in semantic dementia (0 out of 15 cases of semantic dementia in the Cambridge Brain Bank had cerebellar pathology).

    Two independent preprocessing methods were evaluated. (1) The data were coregistered with T1-weighted images. Regions of interest were defined by cortical parcellation and modified subcortical segmentation using the Desikan-Killiany atlas in the PetSurfer toolbox within Freesurfer.20 21 The BPND values in each region were partial volume corrected using the symmetric geometric transfer matrix method.22 (2) The mean aligned PET image, and hence the corresponding aligned dynamic PET image series, was rigidly registered to the T1-weighted image using SPM8, so as to extract values from the Hammersmith atlas n30r83 (http://brain-development.org/brain-atlases) modified with brainstem and cerebellar parcellation. All region of interest data, including the reference tissue values, were corrected for the cerebrospinal fluid fraction through division with the mean region of interest probability (normalised to 1) of grey plus white matter segments, each smoothed to PET resolution.

    Analysis

    To test hypothesis 1, we used general linear models with t-tests for each region of interest, excluding extraparenchymal regions, first comparing each patient to the control group, as a case series (cf Bevan Jones et al 10). We then compared the patients groupwise to the controls. Data were corrected for multiple comparisons to control the false discovery rate (FDR) at q<0.05.23 24

    To test hypothesis 2, regional binding potentials for each subject were converted to a linear vector. Spearman’s rank order method was used to perform non-parametric correlation with all other subjects, creating a correlation ‘similarity’ matrix of the distribution of BPND, disregarding its absolute intensity. The inverse of this matrix (the ‘dissimilarity’ matrix) formed the input to multidimensional scaling and hierarchical cluster analysis. The performance of both farthest neighbour and average linkage methods was assessed (cf Passamonti et al 13).

    Results

    Figure 1 shows the axial and sagittal views of the T1-weighted images for each participant with semantic dementia, confirming the severe asymmetric temporal polar atrophy in svPPA and R-SD, respectively. Also shown are the uncorrected raw [18F]AV-1451 BPND maps for each individual patient and a representative control. Statistical comparisons against controls using method 1 are shown for each patient individually and for the group. All patients had significant elevation of BPND in temporal lobes compared with controls, and in all but one individual, this survived correction for multiple comparisons across the whole brain. As a group, for method 1, significant elevation of BPND at false discovery rate (FDR q<0.05 was observed in the following regions of the left hemisphere: superior, middle and inferior temporal lobes; insula cortex; fusiform gyrus; temporal banks and accumbens. In the right hemisphere: amygdala, caudate and superior temporal cortex. For method 2, the following regions showed significant elevation of BPND at FDR q<0.05. In the left hemisphere: medial anterior and lateral anterior temporal lobes; superior, middle and inferior temporal gyri; fusiform gyrus; insula; thalamus and nucleus accumbens. In the right hemisphere: lateral anterior temporal lobe; middle and inferior temporal gyri and medial anterior temporal lobe.

    Figure 1
    Figure 1

    Using data preprocessed by method 1. (Upper panel) Column 1: axial and sagittal views of T1-weighted images for each semantic dementia participant, column 2: raw axial and sagittal BPND maps for each patient, column 3: unthresholded surface-rendered regional T-maps for each subject against all controls and column 4: equivalent T-maps thresholded at q<0.05, corrected for false discovery rate. (Lower panel) T1-weighted images and BPND maps for a representative control and the group comparisons of all 7 patients versus 12 controls both uncorrected (column 3) and corrected for false discovery rate q<0.05 (column 4). The numbering of individual patients is consistent with figure 2 and table 1. BPND, non-displaceable binding potential. FDR, false discovery rate.

    Non-parametric multidimensional scaling of BPND distribution clearly separated patients from controls (figure 2). With either preprocessing method, hierarchical cluster analysis of these data detected SD with 86% sensitivity and 100% specificity. Cluster analysis, blinded by non-parametric methods to the degree of ligand binding, therefore provided statistically significant unsupervised classification (Yates’ corrected χ2(1, n=19)=11.3, p=0.0008). Identical results were obtained with both average and farthest neighbour linkage methods. The patient misclassified as a control had mild and relatively early disease and lay between the control and patient distributions on multidimensional scaling (figure 2, case L7).

    Figure 2
    Figure 2

    Two-dimensional scaling of non-parametric whole brain regional correlations using data preprocessed by method 1. Red dots represent patients, and green dots controls. Patient labels correspond to individuals in table 1.

    Discussion

    We present evidence for consistently elevated [18F]AV-1451 BPND in seven cases with either svPPA or its non-dominant right hemisphere homologue, R-SD. Contrary to the null hypotheses, in all seven cases individually and at the group level, the regions known to be most affected by TDP-43 pathology25 26 demonstrated increased [18F]AV-1451 binding compared with controls. This did not merely reflect a global increase in BPND, as six of the seven cases were correctly classified by the relative distribution of BPND across the brain. The significant regional binding to likely TDP-43 pathology in svPPA and R-SD indicates that this ligand is not selective for tau and casts doubt on the utility of [18F]AV-1451 to subtype frontotemporal dementias according to tau versus TDP-43 pathology. While this suggests that the use of [18F]AV-1451 to select tau-mediated frontotemporal dementia populations for clinical trials is unlikely to be effective, the ligand may still retain a potential role in the longitudinal assessment of the degree and distribution of pathological burden across the frontotemporal dementia spectrum.

    Semantic dementia in the form of svPPA represents a highly stereotyped and well-defined clinical syndrome with characteristic structural neuroimaging.27–29 Its non-dominant homologue displays similar features but typically with a later presentation, more behavioural disturbance and prosopagnosia.30 Within the spectrum of frontotemporal dementias, both svPPA and R-SD show very strong clinicopathological correlations with TDP-43 pathology, especially type C.4 15 25 26 31 This contrasts with the behavioural variant of frontotemporal dementia which can result from either TDP-43 or tau pathology with approximately equal likelihood.

    Although the majority of semantic dementia cases have TDP-43 pathology, a small minority of cases may arise from tauopathies, most often Alzheimer’s disease pathology or Pick’s disease pathology.15 16 31 In keeping with this, 25 of 34 patients clinically diagnosed with semantic dementia (or svPPA) and in the Cambridge Brain Bank are positive for ubiquitin or TDP-43 and negative for both tau and beta-amyloid. Similarly, the recent report of postmortem examination in clinical cases of svPPA at four centres in North America16 confirmed that the majority (24/29) had TDP-43 pathology (mainly type C). The five who did not have TDP-43 pathology exhibited clinical features out of keeping with the classical syndrome of svPPA, such as short disease duration and extrapyramidal features. These features are not present in any of the individuals we report. Although we do not have autopsy confirmation of the cases reported here, four out of seven participants have negative biomarkers for Alzheimer’s pathology and, overall, it is highly unlikely that the explanation for our findings is that all individuals in our study had a primary or secondary tauopathy.

    While the in vivo and postmortem studies of [18F]AV-1451 in Alzheimer’s disease are compelling, the binding characteristics of [18F]AV-1451 in non-AD tauopathies remain controversial. In vivo studies have been encouraging, with significant binding demonstrated in frontotemporal dementia due to mutations in the MAPT) gene10 12 32 and in progressive supranuclear palsy.13 This contrasts with reports from postmortem studies, which predominantly describe low level binding to the tau aggregates of frontotemporal lobar degeneration.14 33 34 These postmortem studies make it increasingly clear that the primary, tertiary and quaternary structures of tau, as well as the type and maturity of tau pathology,34 are important determinants of [18F]AV-1451 binding. This implies that the predominantly straight filaments of 4-repeat tau that constitute the pathology of progressive supranuclear palsy and corticobasal degeneration, and the 3-repeat tau of intraneuronal Pick bodies, lead to less intense binding than that seen in Alzheimer’s pathology, with its balanced 3-/4-repeat tauopathy in the form of paired helical filaments.

    The discordance between in vivo and postmortem findings led to the proposal of ‘off target’ binding sites. In the last 2 years, several possibilities have been hypothesised, particularly to explain the characteristic pattern of basal ganglia binding seen in almost all participants. These include neuromelanin,33 35 iron, calcium and Biondi ring tangles.34 None of these potential targets is anatomically compatible with the pattern of cortical binding seen here, which is in a distribution expected for pathology in semantic dementia.25 31 One plausible explanation for the elevated signal observed here could be spill out from increased binding in white matter, for example, to the expression of monoamine oxidase B by reactive astrocytes. The intrinsic resolution of PET, combined with the degree of atrophy in the semantic dementia cohort, makes it very difficult to distinguish binding in white or grey matter. However, there is a paucity of evidence for [18F]AV-1451 binding to monoamine oxidase B, unlike other tau radioligands such as the THK compounds. The possibility of binding to monoamine oxidase B was explored early in the development of [18F]AV-1451,5 36 and its favourable profile in this regard was important in its progress to clinical studies.

    Another possibility is that [18F]AV-1451 binds to very low levels of abnormal tau that have been reported to coexist with TDP-43 in some cases,25 to proteins associated with cellular stress in TDP-43 pathologies or to some other cellular marker of neurodegeneration. Alternatively, it could be that the in vivo binding demonstrated here mirrors the postmortem binding of [18F]AV-1451 to TDP-43 type C,14 34 despite the low level or absent binding to most TDP-43 pathology.14 34 Overall, we retain an open mind as to the identity of the non-Tau proteins and cell types to which [18F]AV-1451 is binding in semantic dementia.

    One must also consider some caveats in the analytical methods of the imaging pipelines. In particular, the extreme regional atrophy of semantic dementia complicates normalisation and PET analysis, including modelling decisions such as partial volume correction, which is necessary in order to prevent significant binding being obscured by the degree of atrophy. Misregistration errors arising from extreme atrophy may also influence PET estimates. However, these considerations are unlikely to account for our findings for two main reasons. First, the bright signal of elevated [18F]AV-1451 binding is visible in the temporal lobes of uncorrected BPND maps in all single subjects in native space (figure 1). Second, highly similar patterns of significant binding are seen with two independent methods of data preprocessing, using different tissue segmentation and correction methods and parcellation with different brain atlases. The use of an appropriate reference tissue region may also be complicated in neurodegenerative diseases. In particular, there is emerging evidence that specific patterns of atrophy occur in the cerebellum across a range of disorders.37 In frontotemporal dementia, cerebellar atrophy and pathology are well described in cases of the behavioural variant and particularly in cases resulting from expansions in C9orf72.38 However, in semantic dementia, cerebellar atrophy has not been described, and the typical distribution of TDP-43 type C pathology does not involve the cerebellum.39 We have examined 15 cases of semantic dementia in the Cambridge Brain Bank, and in no case was cerebellar pathology found. Additional reassurance that our results are not driven by a possible group difference in cerebellar pathology comes from our hierarchical cluster analysis. This non-parametric analysis of the distribution of pathology across the whole brain is blind to absolute BPND values; the effect of a group difference in a reference region would be to change the overall level of binding across the brain, without modifying the relative distribution of pathology. The fact that we were able to recover the group structure with 86% sensitivity and 100% specificity argues against cerebellar pathology being a significant driver of our findings.

    Validation of the specificity of [18F]AV-1451 binding in both Alzheimer’s disease and frontotemporal lobar degeneration is highly important. Binding in the presence of neurodegeneration without tauopathy poses serious questions for both clinical and research applications of this ligand, although it may nonetheless be useful to evaluate the progression of neurodegenerative diseases and normal ageing. The magnitude of elevations in binding potential was similar to those previously observed in MAPT mutation10 and progressive supranuclear palsy, but lower than those observed in Alzheimer’s disease.13 While this study did not directly compare FTD-TDP (in semantic dementia) to FTD-tau cases, the lack of selectivity of [18F]AV-1451 for tauopathies challenges the utility of this ligand for pathological differentiation in vivo. Determining the binding site or sites will be important as, even if this is not specific to tau aggregation, it may provide valuable insights into the cellular mechanisms of neurodegeneration, perhaps in regions that are yet to display volume loss or hypometabolism. In order to determine the best use of this ligand, full characterisation of the behaviour of [18F]AV-1451 in frontotemporal lobar degeneration with longitudinal imaging and postmortem validation is essential.

    Acknowledgments

    We thank our volunteers for participating in this study and to the radiographers/technologists at the Wolfson Brain Imaging Centre and PET/CT Unit, Addenbrooke’s Hospital, for their invaluable support in data acquisition. We thank the NIHR Dementias and Neurodegenerative Diseases Research Network for help with subject recruitment. We also thank Dr’s Istvan Boros, Joong-Hyun Chun and WBIC RPU for the manufacture of [18F]AV-1451. We thank Avid (Lilly) for supplying the precursor for the manufacturing of [18F]AV-1451 for use in this study.

    References

    1. ↵
      2. Klunk WE ,
      3. Engler H ,
      4. Nordberg A , et al
      . Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306–19.doi:10.1002/ana.20009
      OpenUrlCrossRefPubMedWeb of Science
    2. ↵
      2. Mackenzie IR ,
      3. Neumann M ,
      4. Bigio EH , et al
      . Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol 2009;117:15–18.doi:10.1007/s00401-008-0460-5
      OpenUrlCrossRefPubMed
    3. ↵
      2. Mackenzie IR ,
      3. Neumann M ,
      4. Bigio EH , et al
      . Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol 2010;119:1–4.doi:10.1007/s00401-009-0612-2
      OpenUrlCrossRefPubMedWeb of Science
    4. ↵
      2. Mackenzie IR ,
      3. Neumann M ,
      4. Baborie A , et al
      . A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol 2011;122:111–3.doi:10.1007/s00401-011-0845-8
      OpenUrlCrossRefPubMedWeb of Science
    5. ↵
      2. Xia CF ,
      3. Arteaga J ,
      4. Chen G , et al
      . [18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer’s disease. Alzheimers Dement 2013;9:666–76.doi:10.1016/j.jalz.2012.11.008
      OpenUrlCrossRefPubMedWeb of Science
    6. ↵
      2. Ossenkoppele R ,
      3. Schonhaut DR ,
      4. Schöll M , et al
      . Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease. Brain 2016;139:1551–67.doi:10.1093/brain/aww027
      OpenUrlCrossRefPubMed
    7. ↵
      2. Schwarz AJ ,
      3. Yu P ,
      4. Miller BB , et al
      . Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. Brain 2016;139:1539–50.doi:10.1093/brain/aww023
      OpenUrlCrossRefPubMed
    8. ↵
      2. Johnson KA ,
      3. Schultz A ,
      4. Betensky RA , et al
      . Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol 2016;79:110–9.doi:10.1002/ana.24546
      OpenUrlCrossRefPubMed
    9. ↵
      2. Schöll M ,
      3. Lockhart SN ,
      4. Schonhaut DR , et al
      . PET imaging of tau deposition in the aging human brain. Neuron 2016;89:971–82.doi:10.1016/j.neuron.2016.01.028
      OpenUrlCrossRefPubMed
    10. ↵
      2. Bevan Jones WR ,
      3. Cope TE ,
      4. Passamonti L , et al
      . [18F]AV-1451 PET in behavioral variant frontotemporal dementia due to MAPT mutation. Ann Clin Transl Neurol 2016;3:940–7.doi:10.1002/acn3.366
      OpenUrl
    11. ↵
      2. Smith R ,
      3. Puschmann A ,
      4. Schöll M , et al
      . 18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers. Brain 2016;139:2372–9.doi:10.1093/brain/aww163
      OpenUrlCrossRefPubMed
    12. ↵
      2. Spina S ,
      3. Schonhaut DR ,
      4. Boeve BF , et al
      . Frontotemporal dementia with the V337M MAPT mutation: tau-PET and pathology correlations. Neurology 2017;88:758–66.doi:10.1212/WNL.0000000000003636
      OpenUrl
    13. ↵
      2. Passamonti L ,
      3. Vazquez Rodriguez P ,
      4. Hong YT , et al
      . 18F-AV-1451 positron emission tomography in Alzheimer’s disease and progressive supranuclear palsy F-AV-1451 positron emission tomography in Alzheimer’s disease and progressive supranuclear palsy. Brain 2017;140:1–11.
      OpenUrlCrossRefPubMed
    14. ↵
      2. Sander K ,
      3. Lashley T ,
      4. Gami P , et al
      . Characterization of tau positron emission tomography tracer [18F]AV-1451 binding to postmortem tissue in Alzheimer’s disease, primary tauopathies, and other dementias. Alzheimers Dement 2016;12:1116–24.doi:10.1016/j.jalz.2016.01.003
      OpenUrl
    15. ↵
      2. Hodges JR ,
      3. Mitchell J ,
      4. Dawson K , et al
      . Semantic dementia: demography, familial factors and survival in a consecutive series of 100 cases. Brain 2010;133:300–6.doi:10.1093/brain/awp248
      OpenUrlCrossRefPubMedWeb of Science
    16. ↵
      2. Spinelli EG ,
      3. Mandelli ML ,
      4. Miller ZA , et al
      . Typical and atypical pathology in primary progressive aphasia variants. Ann Neurol 2017;81:430–43.doi:10.1002/ana.24885
      OpenUrl
    17. ↵
      2. Bevan-Jones WR ,
      3. Surendranathan A ,
      4. Passamonti L , et al
      . Neuroimaging of Inflammation in Memory and Related Other Disorders (NIMROD) study protocol: a deep phenotyping cohort study of the role of brain inflammation in dementia, depression and other neurological illnesses. BMJ Open 2017;7:1–9.doi:10.1136/bmjopen-2016-013187
      OpenUrl
    18. ↵
      2. Gorno-Tempini ML ,
      3. Hillis AE ,
      4. Weintraub S , et al
      . Classification of primary progressive aphasia and its variants. Neurology 2011;76:1006–14.doi:10.1212/WNL.0b013e31821103e6
      OpenUrlCrossRefPubMed
    19. ↵
      2. Kinahan PE ,
      3. Rogers JG
      . Analytic 3D image reconstruction using all detected events. IEEE Trans Nucl Sci 1989;36:964–8.doi:10.1109/23.34585
      OpenUrlCrossRefWeb of Science
    20. ↵
      2. Greve DN ,
      3. Svarer C ,
      4. Fisher PM , et al
      . Cortical surface-based analysis reduces bias and variance in kinetic modeling of brain PET data. Neuroimage 2014;92:225–36.doi:10.1016/j.neuroimage.2013.12.021
      OpenUrlCrossRefPubMed
    21. ↵
      2. Greve DN ,
      3. Salat DH ,
      4. Bowen SL , et al
      . Different partial volume correction methods lead to different conclusions: an 18F-FDG-PET study of aging. Neuroimage 2016;132:334–43.doi:10.1016/j.neuroimage.2016.02.042
      OpenUrlCrossRefPubMed
    22. ↵
      2. Sattarivand M ,
      3. Kusano M ,
      4. Poon I , et al
      . Symmetric geometric transfer matrix partial volume correction for PET imaging: principle, validation and robustness. Phys Med Biol 2012;57:7101–16.doi:10.1088/0031-9155/57/21/7101
      OpenUrlCrossRefPubMed
    23. ↵
      2. Genovese CR ,
      3. Lazar NA ,
      4. Nichols T
      . Thresholding of statistical maps in functional neuroimaging using the false discovery rate. Neuroimage 2002;15:870–8.doi:10.1006/nimg.2001.1037
      OpenUrlCrossRefPubMedWeb of Science
    24. ↵
      2. Benjamini Y ,
      3. Hochberg Y
      . Controlling the false discovery rate : a practical and powerful approach to multiple testing. J R Statist Soc B 1995;57:289–300.
      OpenUrl
    25. ↵
      2. Cairns NJ ,
      3. Bigio EH ,
      4. Mackenzie IR , et al
      . Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol 2007;114:5–22.doi:10.1007/s00401-007-0237-2
      OpenUrlCrossRefPubMedWeb of Science
    26. ↵
      2. Josephs KA ,
      3. Hodges JR ,
      4. Snowden JS , et al
      . Neuropathological background of phenotypical variability in frontotemporal dementia. Acta Neuropathol 2011;122:137–53.doi:10.1007/s00401-011-0839-6
      OpenUrlCrossRefPubMedWeb of Science
    27. ↵
      2. Hodges JR ,
      3. Patterson K ,
      4. Oxbury S , et al
      . Semantic dementia: progressive fluent aphasia with temporal lobe atrophy. Brain 1992;115:1783–806.
      OpenUrlCrossRefPubMedWeb of Science
    28. ↵
      2. Snowden J ,
      3. Goulding P ,
      4. Neary D
      . Semantic dementia : a form of circumscribed cerebral atrophy. Behav Neurol 1989;2:167–82.
      OpenUrl
    29. ↵
      2. Warrington EK
      . The selective impairment of semantic memory. Q J Exp Psychol 1975;27:635–57.doi:10.1080/14640747508400525
      OpenUrlCrossRefPubMedWeb of Science
    30. ↵
      2. Chan D ,
      3. Anderson V ,
      4. Pijnenburg Y , et al
      . The clinical profile of right temporal lobe atrophy. Brain 2009;132:1287–98.doi:10.1093/brain/awp037
      OpenUrlCrossRefPubMedWeb of Science
    31. ↵
      2. Snowden J ,
      3. Neary D ,
      4. Mann D
      . Frontotemporal lobar degeneration: clinical and pathological relationships. Acta Neuropathol 2007;114:31–8.doi:10.1007/s00401-007-0236-3
      OpenUrlCrossRefPubMedWeb of Science
    32. ↵
      2. Smith R ,
      3. Puschmann A ,
      4. Schöll M , et al
      . 18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers. Brain 2016;139:2372–9.doi:10.1093/brain/aww163
      OpenUrlCrossRefPubMed
    33. ↵
      2. Marquié M ,
      3. Normandin MD ,
      4. Vanderburg CR , et al
      . Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol 2015;78:787–800.doi:10.1002/ana.24517
      OpenUrlCrossRefPubMed
    34. ↵
      2. Lowe VJ ,
      3. Curran G ,
      4. Fang P , et al
      . An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathol Commun 2016;4:58.doi:10.1186/s40478-016-0315-6
      OpenUrl
    35. ↵
      2. Hansen AK ,
      3. Knudsen K ,
      4. Lillethorup TP , et al
      . In vivo imaging of neuromelanin in Parkinson’s disease using 18F-AV-1451 PET. Brain 2016;139:2039–49.doi:10.1093/brain/aww098
      OpenUrlCrossRefPubMed
    36. ↵
      2. Chien DT ,
      3. Bahri S ,
      4. Szardenings AK , et al
      . Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis 2013;34:457–68.doi:10.3233/JAD-122059
      OpenUrlCrossRefPubMedWeb of Science
    37. ↵
      2. Gellersen HM ,
      3. Guo CC ,
      4. O’Callaghan C , et al
      . Cerebellar atrophy in neurodegeneration-a meta-analysis. J Neurol Neurosurg Psychiatry 2017;88:780–8.doi:10.1136/jnnp-2017-315607
      OpenUrlAbstract/FREE Full Text
    38. ↵
      2. Whitwell JL ,
      3. Weigand SD ,
      4. Boeve BF , et al
      . Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. Brain 2012;135:794–806.doi:10.1093/brain/aws001
      OpenUrlCrossRefPubMedWeb of Science
    39. ↵
      2. Davies RR ,
      3. Hodges JR ,
      4. Kril JJ , et al
      . The pathological basis of semantic dementia. Brain 2005;128:1984–95.doi:10.1093/brain/awh582
      OpenUrlCrossRefPubMedWeb of Science

    Footnotes

    • JTO’B and JBR contributed equally.

    • Contributors Conceptualisation: JBR, JTOB and FIA; methodology: PSJ, TEC, JBR and WRBJ; investigation: WRBJ, LP, RA and KSJA; formal analysis: YTH, TDF, PSJ and TEC; resources: FIA, TDF, YTH and JPC. Writing: original draft: WRBJ; review and editing: TEC, PSJ, JBR, JTOB, LP and KP; funding acquisition: JBR and JTOB; supervision: JBR, JTOB, FIA and KP.

    • Funding This work was supported by the National Institute for Health Research Biomedical Research Centre and Biomedical Research Unit in Dementia; the Wellcome Trust (JBR 103838); the Association of British Neurologists and the Patrick Berthoud Charitable Trust (TEC).

    • Competing interests None declared.

    • Ethics approval NRES Committee East of England—Central Cambridge.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    Linked Articles